Sunesis Pharmaceuticals to Participate in Upcoming Investor Conferences
March 04 2019 - 6:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that
the Company will participate in three upcoming investor conferences
in March:
Event: Cowen and Company 39th
Annual Health Care Conference Date: Monday, March 11th
Presentation Time: 4:10 p.m. Eastern Time Location: Boston,
MA
Event: Oppenheimer 29th Annual Healthcare
Conference Date: Tuesday, March 19th Presentation Time: 4:30 p.m.
Eastern Time Location: New York City, NY
Event: 31st Annual ROTH Conference
Date: Tuesday, March 19th Panel Time: 8:30 a.m. Pacific Time
Location: Laguna Niguel, CA
Live webcasts of the Cowen and Oppenheimer
presentations will be available on the Sunesis website
at http://ir.sunesis.com. A replay will be archived on
the "Calendar of Events" page in the Investors and Media section of
the Sunesis website for two weeks.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing new targeted therapeutics for the treatment of
hematologic and solid cancers. Sunesis has built an experienced
drug development organization committed to improving the lives of
people with cancer. The Company is focused on advancing its novel
kinase inhibitor pipeline, with an emphasis on its oral
non-covalent BTK inhibitor vecabrutinib. Vecabrutinib is currently
being evaluated in a Phase 1b/2 study in adults with chronic
lymphocytic leukemia and other B-cell malignancies that have
progressed after prior therapies. The Company’s proprietary PDK1
inhibitor SNS-510 is in preclinical development. PDK1 is a master
kinase that activates other kinases important to cell growth and
survival including members of the AKT, PKC, RSK, and SGK families.
Sunesis is exploring strategic alternatives for vosaroxin, a
late-stage investigational product for relapsed or refractory AML.
Sunesis also has an interest in the pan-RAF inhibitor TAK-580 which
is licensed to Takeda. TAK-580 is in a clinical trial for pediatric
low-grade glioma.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis
Pharmaceuticals, Inc.
Investor and Media Inquiries: |
|
|
|
Maeve Conneighton |
|
|
Willie Quinn |
Argot Partners |
|
|
Sunesis Pharmaceuticals Inc. |
212-600-1902 |
|
|
650-266-3716 |
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Apr 2024 to May 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Sunesis Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles